Using BIS monitoring to assess sepsis severity in critically ill patients
Sensitivity and Specificity of Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis, Severe Sepsis and Septic Shock and Multiple Organ Failure (MOF)
This study tests if using a special brain monitoring tool can help doctors understand how severe sepsis is in critically ill patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Sex | All |
| Sponsor | Suez Canal University Academic / other |
| Locations | 1 site (Dalian, Dalian) |
| Trial ID | NCT03244293 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of Bispectral Index (BIS) monitoring in classifying the severity of sepsis in critically ill patients. It aims to correlate BIS values with procalcitonin (PCT) graded sepsis levels and other clinical parameters such as C-reactive protein, Glasgow coma scale, and sequential organ failure assessment scores. The study involves measuring BIS values over time to monitor changes in the patient's mental state and sepsis condition. No interventions are administered, as the focus is on observational data collection.
Who should consider this trial
Good fit: Ideal candidates for this study are critically ill patients diagnosed with sepsis.
Not a fit: Patients who have received medications that interfere with BIS monitoring will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the monitoring and management of sepsis in critically ill patients, potentially leading to better outcomes.
How similar studies have performed: While the use of BIS monitoring in sepsis is a novel approach, similar studies have shown promise in utilizing monitoring technologies for critical care assessments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients with sepsis * patients with sepsis Exclusion Criteria: * Patients who received drugs that would interfere with BIS monitoring
Where this trial is running
Dalian, Dalian
- Dalian Medical University — Dalian, Dalian, China (Recruiting)
Study contacts
- Principal investigator: Ashraf Dahaba, MD, MSc — Suez Canal University
- Study coordinator: Ashraf Dahaba
- Email: ashraf.dahaba@medunigraz.at
- Phone: 00436509006761
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.